Tag: Pakistan

Posted on

Duck Creek Technologies Announces Winners of Its Inaugural 2023 Duck Creek Technologies Partner of the Year Awards

Systems Integrator Partners Accenture, Aggne and Coforge; Solution Partners Copart, LexisNexis Risk Solutions, Quadient, and Smart Communications and Consulting Partner Penguin Tech are each recognized for meaningful technology innovations to the insurance industry during Duck Creek’s Partner Summit ’23

BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) — Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, announces today the winners for the company’s inaugural 2023 Duck Creek Technologies Partner of the Year Awards during its annual Partner Summit ’23, held in Orlando, Florida, September 20-21, 2023. Receiving Duck Creek’s 2023 Partner of the Year Awards were Systems Integrator Partners Accenture, Aggne and Coforge; Solution Partners Copart, LexisNexis Risk Solutions, Smart Communications, and Quadient; and consulting partner Penguin Tech.

The SaaS (software-as-a-service) leader dedicated time during their event to recognize the incredible accomplishments of their solution partners, systems integrators and consulting partners worldwide. The Duck Creek Technologies Partner of the Year Awards were created to acknowledge the power of partnerships and celebrate significant joint achievements across the insurance ecosystem. Engraved glass awards were handed to the eight winners for achieving the highest level of excellence as a partner to Duck Creek and for having a vision to advance their business while reimagining the future of insurance.

Accenture was recognized as System Integrator Partner of the Year for excelling in joint go-to-market activities, delivering Duck Creek solutions to customers across the globe, and consistently exceeding delivery adherence standards.​ Accenture has achieved the highest number of completed implementations across Duck Creek solutions and maintains its position as a significant influence for global customer upsells.

Aggne was recognized as Americas Value Creation Partner of the Year for successful collaboration with Duck Creek sales teams to differentiate and win new business and development of accelerators to ensure successful migration of customers to Duck Creek OnDemand (DCOD).

Coforge was recognized as International Value Creation Partner of the Year for providing exceptional delivery of packaged services to customers, realizing faster time to value from Duck Creek.​ Coforge successfully deployed prepackaged Duck Creek OnDemand solutions using accelerators and best practices in record time.

Copart was recognized as Operational Efficiency Solution Partner of the Year for its integration with Duck Creek. It improves operational efficiency for our mutual customers, enabling them to make intelligent insurance decisions and quickly meet policyholders’ needs. Copart has been a valued go-to-market partner for Duck Creek in the top 10 auto insurer market and provides an industry-leading auto salvage service central to Duck Creek’s automotive claims strategy. Its robust integration with Duck Creek provides a demonstrable example of simultaneously improving operational efficiency and customer experience.

LexisNexis Risk Solutions was recognized as Speed-to-Market Solution Partner of the Year for its integrations with Duck Creek, significantly impacting our mutual customers’ speed to market. LexisNexis Risk Solutions has been a partner of Duck Creek for fourteen years. It offers ten pre-built integrations for its industry-leading solutions. Its integrations are more consistently adopted than others, resulting in quicker implementation time and cost savings for our mutual customers.

Quadient was recognized as Personalized Experiences Solution Partner of the Year for providing a compelling solution integration to better personalize the policyholder experience. Quadient is a leader in customer communications management with integrations available for Duck Creek Policy and Claims. Quadient engaged closely with Duck Creek during 2023 in various co-marketing activities around these integrations, resulting in multiple new sales opportunities for both parties.

Smart Communications was recognized as International Solution Partner of the Year for significantly contributing globally to Duck Creek’s business. Smart Communications is a recognized global leader in customer communications management. In 2023, their team stood out by collaborating extensively with Duck Creek’s team to develop key demonstration integrations jointly and sponsored our first annual customer summit for our APAC region.

Penguin Tech was recognized as Consulting Partner of the Year for making significant contributions to the value of the Duck Creek ecosystem. The Penguin Tech team has over 40 years of combined Duck Creek experience and accelerated the growth of the Duck Creek ecosystem by developing many integrations on behalf of our Solution Partners. These integrations with market leaders have created compelling sales demonstrations and extended the Duck Creek value proposition.

“We are thrilled by the valuable partnerships we’ve formed and our capacity to engage collaboratively with distinguished companies such as Accenture, Aggne, Coforge, Copart, LexisNexis, Quadient, Smart Communications, and Penguin Tech. Together, we are reshaping the landscape of innovation in the insurance industry as we continue delivering top-tier cloud-based solutions paired with exceptional services,” said Mike Jackowski, CEO, Duck Creek Technologies. “It is a privilege to recognize these achievements and commemorate the accomplishments of our partners at our Partner Summit ’23, with an audience comprising hundreds of fellow ecosystem members.”

For more information about these award-winning Duck Creek partners, visit https://www.duckcreek.com/partner/ and these partner websites:

Systems Integrator award winners:

Accenture

Aggne

Coforge

Solution Partner award winners:

Copart

LexisNexis Risk Solutions

Quadient

Smart Communications

Consulting Partner award winner:

Penguin Tech

About Duck Creek Technologies

Duck Creek Technologies is the intelligent solutions provider defining the future of the property and casualty (P&C) and general insurance industry. We are the platform upon which modern insurance systems are built, enabling the industry to capitalize on the power of the cloud to run agile, intelligent, and evergreen operations. Authenticity, purpose, and transparency are core to Duck Creek, and we believe insurance should be there for individuals and businesses when, where, and how they need it most. Our market-leading solutions are available on a standalone basis or as a full suite, and all are available via Duck Creek OnDemand. Visit www.duckcreek.com to learn more. Follow Duck Creek on our social channels for the latest information – LinkedIn and Twitter.

Media Contacts:
Carley Bunch
carley.bunch@duckcreek.com

GlobeNewswire Distribution ID 8925918

Posted on

WilsonHCG named No. 1 global RPO provider in HRO Today’s 2023 RPO Baker’s Dozen List

TAMPA, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) — WilsonHCG has been recognized as the No. 1 Recruitment Process Outsourcing (RPO) provider in HRO Today’s 2023 Baker’s Dozen List.

The longest-standing customer satisfaction survey in the RPO industry, HRO Today’s Baker’s Dozen List is designed to highlight the world’s top RPO providers and lends transparency into the RPO partnerships that are most impactful. Providers are rated on a range of factors including breadth of solutions, quality of service and size of deal.

“It’s an honor to be ranked No. 1 in the Baker’s Dozen List,” said John Wilson, CEO at WilsonHCG. “This recognition means so much to us as a business because it’s solely driven by client feedback. It really is a testament to the commitment and care that our people place in our client relationships. I want to say a huge thank you to the team and can’t wait to build on this success as we continue to add even more value to our client partnerships.”

“Since WilsonHCG’s first placement on the HRO Today Baker’s Dozen as a challenger brand, it has focused on great customer service and innovative approaches to recruitment process outsourcing and workforce solutions. It has transitioned from its early days as a challenger to a large and market dominating leader which is helping redefine what success should look like for clients of these service offerings. Remarkably, WilsonHCG’s service orientation has continued to improve as it has grown to one of the largest and most successful companies in the space and we congratulate it and its leadership team on ranking as the top provider on the HRO Today RPO Baker’s Dozen,” said Elliot Clark, CEO of HRO Today.

Visit the HRO Today website here to find more information about the Baker’s Dozen List.

About WilsonHCG
WilsonHCG is an award-winning, global leader in total talent solutions. Operating as a strategic partner, it helps some of the world’s most admired brands build comprehensive talent functions. With a global presence spanning more than 65 countries and six continents, WilsonHCG provides a full suite of configurable talent services including recruitment process outsourcing (RPO), executive search, contingent talent solutions and talent consulting.

TALENT.™ It’s more than a solution, it’s who we are.

www.wilsonhcg.com

Media contact
kirsty.hewitt@wilsonhcg.com

+44 7889901517

813-418-4479

GlobeNewswire Distribution ID 8925480

Posted on

Acino significantly expands presence and capabilities in Latin America through acquisition of M8 Pharmaceuticals

Over 300 M8 employees, product portfolio and pipeline to enhance Acino’s footprint and strategic position in key Latin American markets.

Zurich, Switzerland, Sept. 20, 2023 (GLOBE NEWSWIRE) — Acino, a Swiss pharmaceutical company headquartered in Zurich, today announced that it has entered into an agreement to acquire M8 Pharmaceuticals (M8), a fast-growing specialty biopharmaceutical company, headquartered in Mexico City and focused on licensing, marketing, and distributing innovative and established medicines in Mexico and Brazil.

Through this acquisition, Acino will enter the two largest pharmaceutical markets in Latin America, significantly expanding its geographic footprint and strengthening its position in the region, providing a more powerful and comprehensive offering for healthcare professionals and patients. The acquisition will complement Acino’s existing Latin American division, which is based in Panama and operates across eight countries in Central America, the Caribbean, and Ecuador, delivering high-quality medicines to improve people’s health in this key region.

M8, a Montreux Growth Partners portfolio company, has a highly successful record of signing exclusive licensing agreements with large pharmaceutical and biotech companies for the rights to market and commercialize products in Latin America. M8 brings a portfolio of well-known proven brands and innovative products, a best-in-class deal-making platform and an outstanding reputation among its partners. Moreover, it has built a large pipeline across a broad range of key therapeutic areas, including CNS, cardiometabolism, respiratory, gastroenterology, oncology and hematology, and rare diseases.

Andrew Bird, Interim CEO at Acino commented: “This is a transformative deal for Acino, significantly expanding our presence in Latin America and delivering against our overall strategy and stated intention to increase patient’s access to high-quality pharmaceuticals and diversify our footprint in key high-growth markets. We see M8 and Acino as highly complementary offerings, and we are confident that we can use this acquisition as a catalyst to further increase value and accelerate growth for Acino in this key region.”

Joel Barlan, CEO at M8 commented: “This agreement will provide M8 with considerable additional resources, expertise, and access to a much wider geographic footprint, which will further accelerate our growth. We look forward to leveraging the skills and capabilities of both teams to grow the combined business and continue to bring proven and innovative treatments to patients and caregivers throughout Latin America and other emerging markets.”

Dan Turner, Managing Director at Montreux Growth Partners commented: “We could not be more pleased with what M8 has achieved during our ownership. We first invested in the early stages of its development. We were able to bring on board a world-class management team, who have focused the company on patient critical therapeutic areas, with a product portfolio that now includes over 30 leading brands from major pharmaceutical companies around the world. The company has delivered tremendous growth and profitability, while also doing much good for the lives of patients. Acino is the perfect acquirer to continue that history of success”.

The transaction is subject to customary closing conditions, including antitrust clearance, and is expected to be completed by the end of 2023. Banco J.P. Morgan S.A. is acting as exclusive financial advisor, Goodwin LLP as exclusive legal advisor, and PWC as exclusive accounting and tax advisor to Acino. Stifel, Cooley LLP and Credit Suisse, a UBS Group Company acted as advisors to M8.

About AcinoAcino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, Ukraine, the CIS Region, and Latin America. Acino is part of ADQ, an Abu Dhabi based investment and holding company. We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing.

About M8 Pharmaceuticals

M8 is a specialty biopharmaceutical company focused on licensing, marketing and distributing innovative and established therapeutics in Latin America: Brazil and Mexico. We aim to become the preferred pharmaceutical partner for the licensing of high-value innovative and proven therapies across our main therapeutic areas CNS, respiratory, cardiometabolic, immunology, gastroenterology, onco-hematology, and rare diseases. Our mission is to provide the people of Latin America with access to the proven and innovative medicines they need to transform their lives.

About Montreux Growth Partners

Founded in 1993, Montreux Growth Partners has a long history of investing growth capital into category-leading companies that are advancing healthcare and financial technology. It focuses on commercial stage companies which have highly differentiated products, technologies, and services. It is an active and collaborative investor, working closely with the management teams at its portfolio companies.

Attachment

Acino
Larisa Bernstein, Global Head of Communications
larisa.bernstein@acino.swiss

M8 Pharmaceuticals
Joel Barlan, Chief Executive Officer
+52 (55) 4431 2933 
us.wm@moksha8.com

Rafael Ferrer, Vice President of Corporate Development & Strategy
+1 (305) 299 6998
rafael.ferrer@m8pharma.com

GlobeNewswire Distribution ID 8925525

Posted on

Impulse Dynamics Announces Leadership Changes

Jason Spees Appointed to Chief Executive Officer — Shlomi Nachman To Be Chairman and John Liddicoat To Join the Board of Directors — Expanding Depth of Medical Device Industry Leadership and Track Record of Driving Commercialization Success With Advanced Technology

MARLTON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) — Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure, announced new leadership appointments, including Jason Spees to Chief Executive Officer, Shlomi Nachman to Chairman of the Board, and John Liddicoat, M.D., as a member of the Board of Directors. Spees was recently President and Chief Commercial Officer at Impulse Dynamics and brings a depth of medical device industry experience from commercial leadership roles. Nachman most recently was the Company Group Chairman at Johnson & Johnson, overseeing the Cardiovascular and Specialty Solutions & Vision Group. Liddicoat most recently served as Executive Vice President and President of the Americas Region and Enterprise Technology & Innovation function at Medtronic.

“I am pleased to lead the Impulse Dynamics team, focusing on a strong commercialization strategy and our commitment to an ongoing pace of innovation to change the course of treatment for patients living with heart failure,” said Spees. “We find ourselves in a unique position to capitalize on robust clinical data and a lineup of cutting-edge technologies, exemplified by the Integra-D™ trial featuring the groundbreaking single device that integrates our CCM® technology with implantable cardioverter defibrillator (ICD) technology. I look forward to working closely with the board and the leadership team to optimize the company for its next phase of commercial acceleration.”

“I am honored to join the board of an organization that has showcased substantial contributions to the advancement of heart failure treatment,” said Shlomi Nachman. “Over 64 million people suffer from heart failure, and many of those treated are not experiencing the higher quality of life they deserve. With CCM therapy and its future product pipeline, we are in the exciting position of being able to help millions of these patients to feel better and lead fuller lives,” Nachman added. “I’m looking forward to working with the leadership team and the board to ensure a direct path to ongoing innovation and commercial success.”

“I’ve been watching Impulse Dynamics and its technology from the sidelines for many years, and I am excited to now be able to join the team,” said Liddicoat. “I look forward to working with a strong leadership team to lead innovation-driven growth as we aim to enhance the standard of care for heart failure patients across the globe.”

Jason Spees joined the company as President and Chief Commercial Officer in July 2021. He brings more than two decades of successful leadership roles in the medical device industry. Spees was most recently Senior Vice President of Sales and Marketing for Biotronik in the areas of cardiac rhythm management, cardiovascular intervention, peripheral vascular intervention, diagnostics, and digital health. Prior to Biotronik, Spees was the Chief Commercial Officer of Preventice Solutions, along with multiple leadership positions, including Vice President of Sales for Boston Scientific. He holds a B.S. in Operations Research and Engineering from the United States Air Force Academy and an M.A. in Public Management – Finance from the University of Maryland.

Shlomi Nachman was the Company Group Chairman of Cardiovascular and Specialty Solutions and Visions Group within Johnson & Johnson’s Medical Devices sector. Nachman was a member of the Medical Devices Group Operating Committee, where he led a diverse portfolio of six medical device businesses, including Electrophysiology, Neurovascular Intervention, Ear, Nose & Throat, Breast Aesthetics, Optometry and Ophthalmology. Before that, Nachman had various roles with increased scope and responsibilities, including Worldwide President of Biosense Webster and Cordis. His career at Johnson & Johnson spanned over 27 years, comprising multiple leadership positions with a proven track record of success that has recognized the ability to drive growth, innovation, and architect business turnarounds. Additionally, Nachman has accrued deep knowledge in all aspects of medical devices, such as general management, strategy, L&A, finance, product development, operations, sales and marketing, and research and development. Nachman was born in Israel and holds a B.S. in Management and Economics from the Technion Institute, as well as a diploma in electrical engineering from the Amal Technical School.

John Liddicoat brings a history of transformational leadership focused on execution. He spent 16 years at Medtronic, driving the strategic direction and global operations of increasing size and scope, including the Structural Heart, Cardiac Rhythm, and Heart Failure businesses. In his most recent role as Executive Vice President and President of the Americas region and the Enterprise Innovation and Technology function, he was responsible for designing and implementing go-to-market strategies to deliver above-market growth across North and South America. Liddicoat graduated medical school from the University of Chicago, completed a residency in general and cardiothoracic surgery at Johns Hopkins Hospital, and served on the faculty of Harvard Medical School. An innovator and entrepreneur, he has also served as a consultant to venture capital firms and early-stage medical device companies.

About the Optimizer® Integra CCM-D™ System and CCM® Therapy

The Optimizer Integra CCM-D System is an investigational device that combines CCM therapy and ICD therapy into one device. This device is being used in an FDA-approved Investigational Device Exemption (IDE) study and is not available for sale in the United States.

Impulse Dynamics currently offers the Optimizer system that is FDA-approved and CE-marked. The Optimizer system delivers CCM therapy — the company’s proprietary technology — to the heart. CCM therapy has been designed by Impulse Dynamics to improve the heart’s contraction, allowing more oxygen-rich blood to be pushed out through the body. CCM therapy is indicated to improve the 6-minute hall walk, quality of life, and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline-directed medical therapy, are not indicated for CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent.

CCM therapy delivers non-excitatory electrical pulses from the implantable Optimizer device in a manner designed to improve heart contraction. CCM therapy sends unique electrical pulses to the heart cells during their absolute refractory period. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials, and CCM therapy has been published in more than 120 peer-reviewed journal articles.

About Impulse Dynamics

Impulse Dynamics is dedicated to advancing the treatment of heart failure for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM therapy, which uses the Optimizer technology platform to improve quality of life in heart failure patients. CCM therapy is delivered through the Optimizer system, which includes an IPG implanted in a minimally invasive procedure and approved for commercial use in the United States and 44 countries worldwide. More than 9,000 patients have received the therapy as part of clinical trials and real-world use, where it is proven to be safe and effective for heart failure patients with debilitating symptoms who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com or follow the company on LinkedIn, Twitter, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy, and CCM therapy combined with an ICD delivered via a single device (CCM-D), and the absence of risks associated therewith; the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short-term and long-term benefits of the Optimizer Integra CCM-D System and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.

Rohan More, Global Vice President of Marketing
Impulse Dynamics
856-642-9933
rmore@impulsedynamics.com

Ian Segal, Public and Media Relations Manager
Impulse Dynamics
856-642-9933
isegal@impulsedynamics.com

GlobeNewswire Distribution ID 8924737

Posted on

George Mason University is Virginia’s Top University for Social Mobility and a Top 50 National Public University

Fairfax, VA, Sept. 18, 2023 (GLOBE NEWSWIRE) — Multiple national college rankings released in recent weeks have placed George Mason University among America’s top 50 public universities, top 100 among all public and private institutions, and Virginia’s No. 1 university for social mobility.

Released today, U.S. News & World Report’s Best Colleges 2024 rankings puts Mason at #51 among all public universities and #105 among all universities nationwide. Mason retains its top 20 ranking position for innovation and improved to a top 50 (#49) university for veterans, according to these national rankings.

“The rankings are confirming what we here at Mason and Virginians have known for some time; based on our performance, George Mason University is one of America’s top 50 public universities,” Mason President Gregory Washington said. “Further, today’s rankings reflect the value and performance families are looking for from a college education, and Mason’s year-over-year enrollment increases and placement of our graduates confirm that we are now a destination for graduates from Virginia and beyond.”

Overall rankings 

Mason is now a top 50 public university in the Wall Street Journal Best Colleges in the U.S. (#33, up from #95) and Forbes America’s Top Colleges (#40). In addition, U.S. News & World Report put Mason in a tie at #51 (up from #64) among public universities, and Washington Monthly National University Rankings ranked Mason 60th among public universities.

Among all universities, both public and private, Mason earns a tied ranking of 105th from U.S. News (up from #137), 95th with the Wall Street Journal (up from #179 in 2021), 93rd with Forbes, and 91st with Washington Monthly (up from #94).

Social mobility

The most significant change in this year’s rankings is the addition of social mobility factors to ranking methodologies, in recognition of growing public demand for more affordable, inclusive, and accessible universities. Mason places No. 1 in Virginia across all rankings that measure social mobility. Among public universities nationwide, Mason ranks #41 with the Wall Street Journal and #34 with Washington Monthly, both for social mobility, and #19 in the New York Times Top U.S. Colleges with the Greatest Economic Diversity.

“All students deserve access to a college education and experience that will deliver on a promise to transform their lives and set them up for lifelong success. Mason delivers in access, innovation, excellence, and opportunity. We are not just in the education business—we are in the success business,” added Washington.

Other national recognitions 

These high-profile rankings follow other recent scores that highlight Mason for being one of America’s most inclusive and welcoming universities. FIRE, the Foundation for Individual Rights and Expression, updated its rankings this month, naming Mason No. 8 in the nation for First Amendment observation, up from 17th last year.

Campus Pride also gave Mason its “Best of the Best” designation again for offering safe and welcoming campuses to the LGBTQ+ community, one of just 30 universities in the nation and the only university in Virginia to earn this distinction.

“The measurements of success are starting to change to favor institutions that are more inclusive and less exclusive,” Washington said. “That adjustment is long overdue. Mason is all about helping hard-working students reach their Point B, no matter where their Point A happens to be.”

The university’s total student enrollment has surpassed 40,000 this year, a first for the Commonwealth of Virginia, including the largest freshman class in school history with 4,500 students. Mason’s graduation rates are higher than the national average. In addition, 86% of recent graduates are employed in the greater Washington, D.C. area and 89% in positions related to their career goals.

Currently, about one in four Mason students is in the first generation of their family to attend college, and a slightly higher percentage of Mason students qualifies for Federal Pell Grants, which are awarded to undergraduates with exceptional financial need.

This year, U.S. News also ranked several of Mason’s undergraduate programs in the top 100 nationally, including business, economics, psychology, computer science, and teaching.

Over the years, Mason has been recognized in the numerous college rankings as Virginia’s top public university for diversity, innovation, cybersecurity, homeland security, service to military veterans, and service to students outside the traditional college ages. Check out all of Mason’s updated rankings: gmu.edu/news/rankings.

About George Mason University

George Mason University is Virginia’s largest public research university. Located near Washington, D.C., Mason enrolls more than 40,000 students from 130 countries and all 50 states. Mason has grown rapidly over the past half-century and is recognized for its innovation and entrepreneurship, remarkable diversity, and commitment to accessibility. In 2023, the university launched Mason Now: Power the Possible, a one-billion-dollar comprehensive campaign to support student success, research, innovation, community, and sustainability. www.gmu.edu.

John Hollis
George Mason University
jhollis2@gmu.edu

GlobeNewswire Distribution ID 8924300

Posted on

Correction: “Averting the SaaS Data Apocalypse” by Simon Taylor: A Journey Through the SaaS Data Landscape

New Book is a Comprehensive Exploration of the Rising Threat to Digital Data and the Race to Protect It

Boston, Massachusetts, Sept. 18, 2023 (GLOBE NEWSWIRE) — Please use the below updated release: HYCU, Inc., the fastest growing data protection as a service company is taking a major first step as the digital world is on the brink of a catastrophe. As more companies increasingly rely on Software as a Service (SaaS) solutions, the looming SaaS data apocalypse is quickly emerging as the most significant threat to data in years. Today, Simon Taylor’s new book, “Averting the SaaS Data Apocalypse,” is released to shine a light on this imminent digital threat and share real world examples of what can be done to avoid digital mayhem.

From the meteoric rise of the SaaS data apocalypse to deep dives into how leading organizations, including the Boston Red Sox, Zebra Technologies, and Bain Capital, have navigated these challenging waters, Taylor offers an unparalleled insight into the modern SaaS landscape.

In the book’s foreword, Enrique Salem, Partner at Bain Capital, an investor in HYCU, underscores the importance of Simon Taylor’s work, stating, “From the dawn of the digital era to the explosive growth of data and the intricacies of SaaS, our digital world is brimming with both opportunities and threats. Simon Taylor, through this pivotal book, offers not just insights but a roadmap to navigating these challenges. ‘Averting the SaaS Data Apocalypse’ stands as a beacon for businesses, guiding them through the dynamic times of the data revolution. Simon’s profound perspectives offer a blueprint for a more secure and streamlined digital age, ensuring the safeguarding of our digital tomorrow.”

In this compelling narrative, readers are plunged into a journey through the treacherous landscape of SaaS data sprawl. However, amidst the chaos, HYCU emerges as the beacon of hope with its first of its kind, R-Cloud, low code data protection development platform, leading the charge against this digital threat.

“There are 23,000+ SaaS applications in use globally, and more than 50% of successful ransomware attacks happening through SaaS use, and predictions that a successful ransomware attack will occur every two seconds by 2031, signs of the Apocalypse are clear,” said Taylor. “The purpose of the book is to shed light on this emerging crisis, offer practical recommendations on how to deal with it, and learn from some of the most forward-thinking IT leaders that share their experiences in how to truly avert what is becoming the biggest IT challenge of our lifetime.”

Availability:
“Averting the SaaS Data Apocalypse” is available for purchase on Amazon.com in print and Kindle versions worldwide with the pending release in audiobook format on Audible. For special orders, corporate packages, or a free signed copy, please visit: Signed Copy.

About Simon Taylor:
Simon Taylor is the CEO and founder of HYCU, the world’s fastest growing multicloud data protection company. He has more than 20 years’ experience in go-to-market strategy development, product marketing and channel sales management for the tech industry. He has worked for leading companies such as Comtrade Group, Forrester Research, Putnam Investments and Omgeo.

He received an MBA in international business from IE (Instituto de Empresa) Business School and an undergraduate degree in operations technology from Northeastern University. He is the author of “John’s Book,” an acclaimed full-length novel, and is a board member at Uncornered, an active member of YPO and a Research Fellow at Boston College.

About HYCU
HYCU is the fastest-growing leader in the multi-cloud and SaaS data protection as a service industry. By bringing true SaaS-based data backup and recovery to on-premises, cloud-native and SaaS environments, the company provides unparalleled data protection, migration, disaster recovery, and ransomware protection to thousands of companies worldwide. As an award-winning and recognized visionary in the industry, HYCU solutions eliminate complexity, risk, and the high cost of legacy-based solutions, providing data protection simplicity to make the world safer. With an industry leading NPS score of 91, customers experience frictionless, cost-effective data protection, anywhere, everywhere. HYCU has raised $140M in VC funding to date and is based in Boston, Mass. Learn more at www.hycu.com.

Attachment

Don Jennings
HYCU, Inc.
617-791-1710
don.jennings@hycu.com

GlobeNewswire Distribution ID 8924198

Posted on

Axi launches Axi Select, a pioneering all-inclusive capital allocation programme offering skilled traders funding of up to $1,000,000 USD

Axi Select

xi Select Campaign

 [We see the Trader in You !]

SYDNEY, Australia, Sept. 18, 2023 (GLOBE NEWSWIRE) — Axi a leading global Forex and CFD broker has announced the launch of Axi Select, a groundbreaking capital allocation programme. The programme is specifically crafted to empower traders by offering them a pathway to access capital funding up to $1,000,000 USD and facilitating their progression into professional trading. Setting a new precedent within the industry, Axi Select offers traders the exceptional advantage to join the program with zero registration fees, as well as the opportunity to earn up to 90% of their profits.

Greg Rubin, Head of Axi Select

Greg Rubin, Head of Axi Select

Greg Rubin, Head of Axi Select, says: “Through the introduction of Axi Select, our innovative capital allocation programme, we aim to provide an opportunity for traders to forge long and successful careers, empowering them to realize their lifelong aspirations of becoming professional traders. Our comprehensive programme provides the capital, support, and resources necessary for traders to thrive in the dynamic world of trading. We are committed to fuelling their passion, driving their success, and providing unwavering support as they navigate towards achieving their goals.” The programme offers a range of notable features, including unrestricted trading conditions, the Edge score which allows traders to fine-tune their strategies and enhance their trading performance, and an exclusive trading room which serves as a dedicated hub, offering real-time market updates and curated educational content.

[LEARN MORE AND JOIN AXI SELECT]

The Axi Select programme is only available to clients of AxiTrader Limited. CFDs carry a high risk of investment loss. This content is not available for AU, NZ, and UK clients. For more information, refer to our Terms of Service. Other Fees may apply.

Click here to watch the Axi Select fireside chat

Talking about Axi Select, Louis Cooper, Chief Commercial Officer at Axi, says “At Axi, we take pride in being a brand that consistently brings the edge to life for our customers. Our revolutionary new offering, Axi Select, is the first-of-its-kind among brokers and another true reflection of our brand promise. We have previously allocated $39M to traders in previous programmes and enabled several traders break out into pro trading status. With Axi Select, we will deliver unparalleled opportunities to our traders whilst both redefining the boundaries of what’s possible in trading and reshaping the evolution of the financial industry.”

Axi offers a streamlined process to participate in Axi Select – with no signup or membership fees, traders can effortlessly submit their application and start trading. Upon achieving a designated Edge Score, traders can start to secure capital funding of up to $1,000,000 USD.

With Axi Select access funds of up to $1,000,000

With Axi Select access funds of up to $1,000,000

[LEARN MORE AND JOIN AXI SELECT]

The Axi Select programme is only available to clients of AxiTrader Limited. CFDs carry a high risk of investment loss. This content is not available for AU, NZ, and UK clients. For more information, refer to our Terms of Service. Other Fees may apply.

Click here to watch the Axi Select fireside chat

About Axi

Axi is a global online FX and CFD trading company, trusted by thousands of ambitious customers in 100+ countries around the world. We help all types of traders, trading businesses, banks and financial organizations find the edge they need to achieve their financial goals through informed transactions made on the world’s financial markets. Axi offers a wide range of assets including CFDs for several asset classes including Forex, Shares, Gold, Silver, Oil, Coffee, Indices, and other commodities.

At Axi, we are proud of our reputation as an honest, fair, and trusted broker. Our many awards and ‘Great’ Trustpilot reviews prove we have earned the confidence of customers who value our outstanding service, fast execution, secure payments, segregated funds, and easy withdrawals.

For further enquiries contact service@axi.com

Check out other Axi communication at https://www.axi.com/int/blog/company-news

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d50c2d41-8931-47bd-9b0f-6a5572fb88e4
https://www.globenewswire.com/NewsRoom/AttachmentNg/987d1f0e-63e9-4234-aaaf-6c041d74d3ba
https://www.globenewswire.com/NewsRoom/AttachmentNg/9a391ff3-5046-485a-916e-cca5bbb247b2

PDF accompanying this announcement is available at:
http://ml-eu.globenewswire.com/Resource/Download/1cfa04fb-a4cb-4b4d-b0dc-5b14a9f0aa0f

GlobeNewswire Distribution ID 1000839877